VTRS Q2 2025 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.6B-5.6% YoY

Gross Profit

$1.3B37.2% margin

Operating Income

$233M6.5% margin

Net Income

-$5M-0.1% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

+10.1%

Cash Flow

Operating Cash Flow

$220M

Free Cash Flow

$166M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$38.4B

Total Liabilities

$22.8B

Stockholders' Equity

$15.6B

Cash & Equivalents

$566M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.6B	$3.8B	-5.6%
Gross Profit	$1.3B	$1.4B	-7.8%
Operating Income	$233M	-$240M	+197.1%
Net Income	-$5M	-$326M	+98.6%

Revenue Segments

Brands

$2.3B64%

Generics

$1.3B36%

Geographic Segments

Developed Markets Segment

$2.1B59%

Greater China Segment

$589M16%

Emerging Markets Segment

$557M16%

Japan, Australia and New Zealand Segment

$307M9%